Acei in ckd
Pro Research Analysisby 
Searched over 200M research papers
The Role of ACE Inhibitors in Chronic Kidney Disease (CKD)
Introduction to ACE Inhibitors in CKD
Angiotensin-converting enzyme inhibitors (ACEi) are a cornerstone in the management of chronic kidney disease (CKD). They are primarily used to control blood pressure and reduce proteinuria, which are critical factors in slowing the progression of CKD and preventing cardiovascular events Bhandari2015Zhang2020. However, their efficacy and safety in different stages of CKD, particularly in advanced stages, remain subjects of ongoing research and debate.
ACE Inhibitors in Early-Stage CKD
Benefits in Early-Stage CKD
In early stages of CKD (stages 1 to 3), ACE inhibitors have shown beneficial effects in reducing proteinuria and controlling blood pressure, which are essential in slowing disease progression . Studies have demonstrated that ACE inhibitors can significantly reduce the risk of kidney events, cardiovascular events, and all-cause mortality in non-dialysis CKD patients Zhang2020Xie2016.
Limitations and Uncertainties
Despite these benefits, the evidence for ACE inhibitors' effectiveness in early-stage CKD without diabetes is less conclusive. A review highlighted that there is insufficient evidence to definitively determine their impact on all-cause mortality and cardiovascular events in this subgroup . This indicates a need for further research to establish clear guidelines for ACE inhibitor use in early CKD.
ACE Inhibitors in Advanced CKD
Potential Benefits and Risks
The use of ACE inhibitors in advanced CKD (stages 4 and 5) is more controversial. The STOP-ACEi trial aims to investigate whether discontinuing ACE inhibitors in patients with advanced CKD can stabilize or improve renal function without increasing cardiovascular risks Bhandari2015Ahmed2016. Preliminary findings suggest that while ACE inhibitors are effective in reducing blood pressure and proteinuria, their benefits in advanced CKD are not as clear-cut, and there may be potential risks associated with their continued use .
Comparative Efficacy
A network meta-analysis comparing ACE inhibitors with other antihypertensive drugs found that ACE inhibitors were superior in reducing kidney events, cardiovascular outcomes, and all-cause mortality in non-dialysis CKD stages 3-5 patients . However, the combination of ACE inhibitors with angiotensin receptor blockers (ARBs) did not show additional benefits and was associated with higher risks of hyperkalemia and hypotension .
ACE Inhibitors Post-Acute Kidney Injury (AKI)
Impact on Recovery and Outcomes
For patients who have experienced acute kidney injury (AKI), the use of ACE inhibitors has been associated with lower risks of all-cause mortality, recurrent AKI, and progression to CKD . This suggests that ACE inhibitors may offer a survival benefit and aid in recovery post-AKI, although the risk of hyperkalemia remains a concern and requires careful monitoring .
Conclusion
ACE inhibitors play a crucial role in managing CKD, particularly in early stages where they help reduce proteinuria and control blood pressure. However, their use in advanced CKD and post-AKI requires careful consideration of potential benefits and risks. Ongoing trials like STOP-ACEi will provide more insights into the optimal use of ACE inhibitors in advanced CKD. Clinicians must weigh the benefits of ACE inhibitors against the risks of adverse effects such as hyperkalemia and hypotension, especially in advanced stages of CKD.
Sources and full results
Most relevant research papers on this topic
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
ACEi and ARB show potential benefits in managing early chronic kidney disease in adults without diabetes mellitus.
Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
Aldosterone antagonists reduce proteinuria in chronic kidney disease patients already on ACEis and ARBs but increase the risk of hyperkalemia.
No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy--report from the ItalKid Project database.
ACEi treatment does not significantly modify the naturally progressive course of hypodysplastic nephropathy in children, and further studies are needed before routinely proposing it for anti-progression purposes.
DOI